Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. Genetically engineered lymphocyte (CART) therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with multiple myeloma.To test the safety and efficacy of giving targeting CD138 or B-cell maturation antigen or CD19 or more antigens T cells in treating patients with multiple myeloma that is refractory to further chemotherapy or relapsed(after stem cell transplantation or intensive chemotherapy).
• CD138 or BCMA antigen positive multiple myeloma in patients with no available curative treatment options (such as autologous or allogeneic SCT).
• Relapsed and/or refractory multiple myeloma.
• Relapsed after prior autologous or allogenic SCT.
• Expected survival ≥ 3 months
• Creatinine \< 2.0 mg/dl
• Blood coagulation function: PT and APTT \< 2x normal
• Arterial blood oxygen saturation \> 92%
• Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) \< 3x normal
• Karnofsky scores ≥ 60 and ECOG score ≤ 2
• Adequate venous access for apheresis, and no other contraindications for leukapheresis
• Patients should not take system chemotherapy in one month and immunotherapy in three months prior to CART cells infusion.
• Voluntary informed consent is given